Welcome to
SK life science

Helping patients who are prescribed XCOPRI® (cenobamate tablets) CV get started and continue on therapy as appropriate.

SK life science navigator may assist eligible
patients with the following*:

SK life science navigator
can help patients access XCOPRI® (cenobamate tablets) CV with the following:

Benefits Verification

Determine drug coverage for patients prescribed XCOPRI based on the patient’s individual health plan

Responsive image

Prior Authorization Information

Determine the information that may be necessary to help obtain a PA decision from a patient’s insurer

Responsive image

Patient Assistance Program (PAP)

SK life science Inc., may provide XCOPRI for free to eligible patients who do not have prescription drug or health insurance coverage and who, without assistance, cannot afford XCOPRI

Responsive image Responsive image

Patient Authorization

You can sign a Patient Authorization for the SK life science navigator program electronically. Click the link below to get started.

Patient Authorization

Responsive image

Patient Assistance Program (PAP) Application

You can fill out and sign the Patient Assistance Program (PAP) Application electronically. Click the link below to get started.

SK life science navigator PAP Application

Responsive image

PAP Financial Hardship Letter

If you are applying for the Patient Assistance Program because you are unable to afford your XCOPRI, you are required to complete a financial hardship letter.

Financial Hardship Letter Template

Always talk to a healthcare provider if there are any questions.

Patients must meet eligibility criteria for PAP, which includes: 1) US resident, 2) on-label diagnosis, 3) meets financial threshold, 4) patient is uninsured, functionally uninsured, or has a financial hardship.

Downloadable Resources

Call for XCOPRI treatment support

Should you need additional information, or to speak to a care coordinator, please call 866-756-2844 (866-SK-NAVIG).

© 2023 SK life science Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd.    
PM-US-SKNAG-0030    08/23